Skip to content
Screener

SELLAS Life Sciences Group, Inc. SLS EPS (Diluted)

EPS (Diluted) at other companies

Pfizer logo
PfizerPFE
-$0.04-108%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-$0.48+51.0%
AbbVie logo
AbbVieABBV
$2.03+290%
Immunome logo
ImmunomeIMNM
-$0.65-30.0%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$0.72—
CTO
Citius Oncology, Inc.CTOR
-$0.080.0%

Other financials

Income statement

See full
Revenue-—
Gross profit-—
Operating income-$10.6M-54.6%
Net income-$9.6M-45.5%

Balance sheet

See full
Cash & equivalents$138.3M+447%
Total debt$737.0K0.0%
Total equity$137.7M+426%
Total assets$145.4M+350%

Cash flow

See full
Operating cash flow-$7.6M-3.5%

Valuation

See full
Market cap$2.29B+1,055%
Enterprise value$2.15B+1,289%

Profitability

See full
Gross margin90%-7.4pp
Operating margin-4,195%-4,591pp
Net margin-4,130.1%-4,444pp
FCF margin-300.5%—

Returns & leverage

See full
Return on equity-39.6%-17.4pp
Debt / equity0×0.0×
Current ratio18.8×+13.9×

Where this comes from

Reported directly by SELLAS Life Sciences Group, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: SELLAS Life Sciences Group, Inc.’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 4:01 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001390478-26-000012
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Loss from operations(10,629)(6,873)(19,881)(12,936)
Non-operating income:
Interest income1,0242721,869522
Total non-operating income1,0242721,869522
Net loss$(9,605)$(6,601)$(18,012)$(12,414)
Per share information:
Net loss per common share, basic and diluted$(0.05)$(0.07)$(0.10)$(0.13)
Weighted-average common shares outstanding, basic and diluted189,183,62098,558,567180,878,72093,189,273

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is SELLAS Life Sciences Group, Inc.'s EPS (diluted)?
SELLAS Life Sciences Group, Inc. (SLS) reported EPS (diluted) of -$0.05 in Q2 2026.
How has SELLAS Life Sciences Group, Inc.'s EPS (diluted) changed year-over-year?
SELLAS Life Sciences Group, Inc.'s EPS (diluted) increased by 28.6% year-over-year, from -$0.07 to -$0.05.
What is the long-term trend for SELLAS Life Sciences Group, Inc.'s EPS (diluted)?
Over 4 years (2021 to 2025), SELLAS Life Sciences Group, Inc.'s EPS (diluted) has grown at a -34.2% compound annual growth rate (CAGR), from -$1.33 to -$0.25.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about SELLAS Life Sciences Group, Inc.'s eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude